Please ensure Javascript is enabled for purposes of website accessibility

Better Dividend: Abbott Laboratories vs. Medtronic, Inc.

By Dan Carroll – Mar 4, 2014 at 7:00PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Abbott Labs and Medtronic sport attractive dividends for long-term investors, but which health care giant's the best stock for your financial future?

In the health-care sector, few stocks boast names as well-known as Medtronic (MDT -1.59%) and Abbott Labs (ABT -1.50%). Medtronic's leadership in the medical device sector and Abbott Labs's strength through medical diversity has made it a strong stock for years. Each stock also offers a reliable dividend, with both Medtronic and Abbott belonging to the S&P 500's Dividend Aristocrats-the group of companies that have raised their dividends annually for at least the past 25 years.

But which of these dividends is the better buy? Abbott offers the higher yield by a slight amount and is well-suited to keep that dividend growing with its strong nutritional business and diagnostics unit, but Medtronic's growth in up-and-coming medical device industries and dominance in major niches such as cardiology make it as reliable a stock as there is in health care.

Find out the winner in the video below, as Motley Fool contributor Dan Carroll takes you through the strengths of Abbott and Medtronic's dividends-and which one should be the right call for your portfolio's health.

Dan Carroll has no position in any stocks mentioned. The Motley Fool owns shares of Medtronic. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.